Compare · BTMD vs DFTX
BTMD vs DFTX
Side-by-side comparison of Biote Corp. (BTMD) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTMD and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $6.02B, about 106.1x BTMD ($56.8M).
- Over the past year, BTMD is down 52.1% and DFTX is up 349.0% - DFTX leads by 401.1 points.
- DFTX has been more active in the news (15 items in the past 4 weeks vs 4 for BTMD).
- DFTX has more recent analyst coverage (7 ratings vs 4 for BTMD).
PerformanceBTMD-52.11%DFTX+349.00%
2025-08-26+0.00%2026-08-25
- Company
- Biote Corp.
- Definium Therapeutics Inc.
- Price
- -
- -
- Market cap
- $56.8M
- $6.02B
- 1M return
- -31.32%
- +4.98%
- 1Y return
- -52.11%
- +349.00%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 4
- 15
- Recent ratings
- 4
- 7
Latest BTMD
- Executive Chairman Beer Marc D bought $202,204 worth of shares (131,950 units at $1.53), increasing direct ownership by 122% to 239,744 units (SEC Form 4)
- SEC Form 10-Q filed by Biote Corp.
- Biote Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Biote Reports Second Quarter 2026 Financial Results
- Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call
- Amendment: SEC Form 8-K/A filed by Biote Corp.
- SEC Form 4 filed by Interim CEO Peterson Robert Charles
- SEC Form 4 filed by Director Christensen Bret
- SEC Form 4 filed by Executive Chairman Beer Marc D
- Biote Corp. filed SEC Form 8-K: Leadership Update
Latest DFTX
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder